Published in Urology on February 13, 2010
Role of M2 and M3 muscarinic acetylcholine receptor subtypes in activation of bladder afferent pathways in spinal cord injured rats. Urology (2012) 0.82
Signalling molecules in the urothelium. Biomed Res Int (2014) 0.79
A rat long-lasting cystitis model induced by intravesical injection of hydrogen peroxide. Physiol Rep (2017) 0.77
Effects of nicotinic receptor agonists on bladder afferent nerve activity in an in vitro bladder-pelvic nerve preparation. Brain Res (2016) 0.75
International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev (1998) 5.34
Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature (2000) 4.53
Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol (2007) 2.27
Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells. Proc Natl Acad Sci U S A (2001) 2.17
Mechanisms of disease: involvement of the urothelium in bladder dysfunction. Nat Clin Pract Urol (2007) 2.06
Mechanisms underlying the recovery of lower urinary tract function following spinal cord injury. Prog Brain Res (2006) 1.74
Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro. Br J Pharmacol (2000) 1.69
Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology (2004) 1.67
Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton Autacoid Pharmacol (2002) 1.55
Heterogeneity of muscarinic receptor-mediated Ca2+ responses in cultured urothelial cells from rat. Am J Physiol Renal Physiol (2008) 1.30
Expression of muscarinic and nicotinic acetylcholine receptors in the mouse urothelium. Life Sci (2007) 1.29
Activation of muscarinic receptors in rat bladder sensory pathways alters reflex bladder activity. J Neurosci (2008) 1.26
Therapeutic receptor targets for lower urinary tract dysfunction. Naunyn Schmiedebergs Arch Pharmacol (2007) 1.25
Expression and distribution of cholinergic receptors in the human urothelium. Life Sci (2007) 1.20
Intracellular calcium signaling through the cADPR pathway is agonist specific in porcine airway smooth muscle. FASEB J (2003) 1.17
Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor. J Urol (2006) 1.10
Muscarinic and purinergic receptor expression in the urothelium of rats with detrusor overactivity induced by bladder outlet obstruction. BJU Int (2007) 1.07
Altered muscarinic receptor subtype expression and functional responses in cyclophosphamide induced cystitis in rats. Auton Neurosci (2005) 1.02
Detrusor overactivity induced by intravesical application of adenosine 5'-triphosphate under different delivery conditions in rats. Urology (2005) 1.02
Muscarinic M2 receptor stimulation of Cav1.2b requires phosphatidylinositol 3-kinase, protein kinase C, and c-Src. Circ Res (2004) 0.94
Lower urinary tract symptoms (LUTS) and bladder afferent activity. Neurourol Urodyn (2007) 0.93
Ryanodine receptor subtype 2 encodes Ca2+ oscillations activated by acetylcholine via the M2 muscarinic receptor/cADP-ribose signalling pathway in duodenum myocytes. J Cell Sci (2005) 0.90
Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats. J Urol (2005) 0.87
Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer (2009) 2.64
Unroofed coronary sinus syndrome: diagnosis, classification, and surgical treatment. J Thorac Cardiovasc Surg (2003) 2.50
Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats. Eur Urol (2008) 2.24
Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancer. Urology (2009) 2.23
Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int (2004) 2.11
Urologic complications of diabetes. Diabetes Care (2005) 2.03
Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol (2008) 1.96
Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci (2004) 1.92
Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology (2005) 1.81
Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology (2005) 1.77
Cell delivery: intramyocardial injections or epicardial deposition? A head-to-head comparison. Ann Thorac Surg (2009) 1.76
Mechanisms underlying the recovery of lower urinary tract function following spinal cord injury. Prog Brain Res (2006) 1.74
Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol (2004) 1.65
Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. J Urol (2006) 1.62
Vascular endothelial growth factor in children with congenital heart disease. Ann Thorac Surg (2003) 1.57
Recent advances in understanding the biology of diabetes-associated bladder complications and novel therapy. BJU Int (2005) 1.56
How sacral nerve stimulation neuromodulation works. Urol Clin North Am (2005) 1.55
Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms. Eur Urol (2013) 1.54
Nerve growth factor level in the prostatic fluid of patients with chronic prostatitis/chronic pelvic pain syndrome is correlated with symptom severity and response to treatment. BJU Int (2010) 1.52
Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and -1D adrenergic receptor antagonists, on bladder activity in rats. Neurosci Lett (2002) 1.51
Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group. Int J Urol (2010) 1.51
Association of overactive bladder and C-reactive protein levels. Results from the Boston Area Community Health (BACH) Survey. BJU Int (2011) 1.50
Risk factors for new-onset overactive bladder in older subjects: results of the Fujiwara-kyo study. Urology (2012) 1.49
Bladder overactivity and hyperexcitability of bladder afferent neurons after intrathecal delivery of nerve growth factor in rats. J Neurosci (2006) 1.48
Pathophysiology of urinary incontinence in murine models. Int J Urol (2012) 1.48
Ventricular septal dysfunction after surgical closure of multiple ventricular septal defects. Ann Thorac Surg (2013) 1.47
Appropriate additional pulmonary blood flow at the bidirectional Glenn procedure is useful for completion of total cavopulmonary connection. Ann Thorac Surg (2005) 1.47
Aggressive angiomyxoma in the scrotum expressing androgen and progesterone receptors. Int J Urol (2003) 1.47
Current and future pharmacological treatment for overactive bladder. J Urol (2002) 1.47
Transabdominal ultrasonography of detrusor wall thickness in women with overactive bladder. BJU Int (2009) 1.46
Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium. Neurourol Urodyn (2013) 1.46
Emerging role of botulinum toxin in the treatment of neurogenic and non-neurogenic voiding dysfunction. Curr Urol Rep (2002) 1.44
One-stage repair of severe hypospadias using modified tubularized transverse preputial island flap with V-incision suture. J Pediatr Urol (2008) 1.43
Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc (2003) 1.43
Afferent nerve regulation of bladder function in health and disease. Handb Exp Pharmacol (2009) 1.42
Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int Urol Nephrol (2009) 1.41
Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. J Urol (2002) 1.41
Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int (2006) 1.40
An infected pseudoaneurysm following a modified Blalock-Taussig shunt. Interact Cardiovasc Thorac Surg (2008) 1.39
Inhibitory role of the spinal galanin system in the control of micturition. Urology (2013) 1.39
Cool (TRPM8) and hot (TRPV1) receptors in the bladder and male genital tract. J Urol (2004) 1.36
Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU Int (2006) 1.36
Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Jpn J Clin Oncol (2007) 1.34
Urethral closure mechanisms under sneeze-induced stress condition in rats: a new animal model for evaluation of stress urinary incontinence. Am J Physiol Regul Integr Comp Physiol (2003) 1.32
Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher (2005) 1.30
Transmembrane interaction mediates complex formation between peptidase homologues and Kv4 channels. Mol Cell Neurosci (2005) 1.30
The role of bladder-to-urethral reflexes in urinary continence mechanisms in rats. Am J Physiol Renal Physiol (2004) 1.29
Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. BJU Int (2009) 1.28
Rehabilitation and medical management of the adult with spina bifida. Am J Phys Med Rehabil (2008) 1.26
Changes in afferent activity after spinal cord injury. Neurourol Urodyn (2010) 1.26
Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target. Neurourol Urodyn (2011) 1.25
Therapeutic receptor targets for lower urinary tract dysfunction. Naunyn Schmiedebergs Arch Pharmacol (2007) 1.25
Inhibitory and excitatory perigenital-to-bladder spinal reflexes in the cat. Am J Physiol Renal Physiol (2007) 1.25
An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol (2009) 1.24
Suppression of detrusor-sphincter dyssynergia by immunoneutralization of nerve growth factor in lumbosacral spinal cord in spinal cord injured rats. J Urol (2004) 1.24
Discrepancy between local and central pathological review of radical prostatectomy specimens. J Urol (2010) 1.24
Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Jpn J Clin Oncol (2004) 1.22
Efficacy of a criterion-driven transfusion protocol in patients having pediatric cardiac surgery. J Thorac Cardiovasc Surg (2004) 1.22
The application of botulinum toxin in the prostate. J Urol (2006) 1.22
Bladder Cancer Working Group report. Jpn J Clin Oncol (2010) 1.21
Improved sphincter contractility after allogenic muscle-derived progenitor cell injection into the denervated rat urethra. Urology (2003) 1.21
Fiber kinematics of small intestinal submucosa under biaxial and uniaxial stretch. J Biomech Eng (2006) 1.20
Effect of duloxetine, a norepinephrine and serotonin reuptake inhibitor, on sneeze-induced urethral continence reflex in rats. Am J Physiol Renal Physiol (2008) 1.20
Identification of c-kit-positive cells in the mouse ureter: the interstitial cells of Cajal of the urinary tract. Am J Physiol Renal Physiol (2003) 1.19
Treatment of interstitial cystitis. Urology (2004) 1.19
Evaluation of heart fatty acid-binding protein as a rapid indicator for assessment of myocardial damage in pediatric cardiac surgery. J Thorac Cardiovasc Surg (2004) 1.18
Role of noradrenergic pathways in sneeze-induced urethral continence reflex in rats. Am J Physiol Renal Physiol (2006) 1.18
Simultaneous repair of pectus excavatum and congenital heart disease over the past 30 years. Eur J Cardiothorac Surg (2002) 1.18
Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int (2009) 1.17
The other bladder syndrome: underactive bladder. Rev Urol (2013) 1.17
Delayed treatment of bladder outlet obstruction after sling surgery: association with irreversible bladder dysfunction. J Urol (2004) 1.17
Comparison of leak point pressure methods in an animal model of stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct (2005) 1.16
A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res (2006) 1.15
Clinical outcome of a large-scale multi-institutional retrospective study for locally advanced bladder cancer: a survey including 1131 patients treated during 1990-2000 in Japan. Eur Urol (2004) 1.13
The endoscopic surgical skill qualification system in urological laparoscopy: a novel system in Japan. J Urol (2006) 1.13
Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol (2004) 1.12